← Leaderboards
Renier Joseph Brentjens
Roswell Park Cancer Institute Corp
$12,958,252
Attributed
$15,314,280
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,314,280 · 9
By mechanism
R01$3,860,264 · 1
K12$3,726,344 · 1
P50$3,255,598 · 4
U01$3,245,042 · 1
P01$823,964 · 1
K08$403,068 · 1
Top collaborators
- Simon N Powell6 shared
- David R Spriggs3 shared
- Monika Shah2 shared
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Richard B Bankert$9,763,302
- Steven H Bernstein$2,820,683
Others in their field
Top investigators on “Neoplastic Cell”
- David Heimbrook · Leidos Biomedical Research, Inc.$139,710,838
- Gregory H Reaman · National Childhood Cancer Foundation$31,993,642
- Bruce W Stillman · Cold Spring Harbor Laboratory$25,455,900
- Ralph Parchment · Leidos Biomedical Research, Inc.$25,266,647
- Andrea Califano · Columbia University Health Sciences$22,374,316
- Wendell A Lim · University Of California, San Francisco$22,334,734
Research focus
Neoplastic CellT-LymphocyteDesignTumorMediatingAntigen TargetingClinical TrialsCancer CellCd19 GeneRefractoryBaseImmunePre-ClinicalCytokineRelapseCell SurfaceResponseTumor AntigensTumor MicroenvironmentReceptorClinically RelevantIn VivoFundingCells
Grant awards (32)
Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer$696,801
U01 · FY2025 · CA · contact PI
Project 4: Chimeric Antigen Receptor T Cell Therapy for the Treatment of Acute Myeloid Leukemia$235,096
P50 · FY2025 · CA · contact PI
Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer$671,440
U01 · FY2024 · CA · contact PI
Project 4: Chimeric Antigen Receptor T Cell Therapy for the Treatment of Acute Myeloid Leukemia$374,759
P50 · FY2024 · CA · contact PI
Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer$630,691
U01 · FY2023 · CA · contact PI
Project 4: Chimeric Antigen Receptor T Cell Therapy for the Treatment of Acute Myeloid Leukemia$311,223
P50 · FY2023 · CA · contact PI
Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer$585,015
U01 · FY2022 · CA · contact PI
Project 4: Chimeric Antigen Receptor T Cell Therapy for the Treatment of Acute Myeloid Leukemia$367,707
P50 · FY2022 · CA · contact PI
Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell Lung Cancer$661,095
U01 · FY2021 · CA · contact PI
Project 4: Chimeric Antigen Receptor T Cell Therapy for the Treatment of Acute Myeloid Leukemia$384,163
P50 · FY2021 · CA · contact PI
MSK Paul Calabresi Career Development Award for Clinical Oncology$769,210
K12 · FY2020 · CA
Autologous CD19 Targeted 19-28z+ Tcells for the Treatment of Relapsed Diffuse Large B cell Lymphoma in Transplant Ineligible Elderly Patients$311,063
P50 · FY2020 · CA · contact PI
MSK Paul Calabresi Career Development Award for Clinical Oncology$808,012
K12 · FY2019 · CA
Autologous CD19 Targeted 19-28z+ Tcells for the Treatment of Relapsed Diffuse Large B cell Lymphoma in Transplant Ineligible Elderly Patients$304,515
P50 · FY2019 · CA · contact PI
MSK Paul Calabresi Career Development Award for Clinical Oncology$696,704
K12 · FY2018 · CA
Autologous CD19 Targeted 19-28z+ Tcells for the Treatment of Relapsed Diffuse Large B cell Lymphoma in Transplant Ineligible Elderly Patients$327,436
P50 · FY2018 · CA · contact PI
MSK Paul Calabresi Career Development Award for Clinical Oncology$761,904
K12 · FY2017 · CA
Autologous CD19 Targeted 19-28z+ Tcells for the Treatment of Relapsed Diffuse Large B cell Lymphoma in Transplant Ineligible Elderly Patients$325,884
P50 · FY2017 · CA · contact PI
MSK Paul Calabresi Career Development Award for Clinical Oncology$636,514
K12 · FY2016 · CA
Adoptive Therapy of Ovarian Cancer with Autologous Genetically Modified T Cells$409,610
P01 · FY2016 · CA · contact PI
Autologous CD19 Targeted 19-28z+ Tcells for the Treatment of Relapsed Diffuse Large B cell Lymphoma in Transplant Ineligible Elderly Patients$313,752
P50 · FY2016 · CA · contact PI
Adoptive Therapy of Ovarian Cancer with Autologous Genetically Modified T Cells$414,354
P01 · FY2015 · CA · contact PI
MSK Paul Calabresi Career Development Award for Clinical Oncology$54,000
K12 · FY2015 · CA
Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells$358,720
R01 · FY2013 · CA · contact PI
Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells$381,617
R01 · FY2012 · CA · contact PI
Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells$381,617
R01 · FY2011 · CA · contact PI
Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells$1,951,470
R01 · FY2010 · CA · contact PI
Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells$393,420
R01 · FY2010 · CA · contact PI
Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells$393,420
R01 · FY2009 · CA · contact PI
Genetic Targeting of T cells to B cell malignancies$134,436
K08 · FY2005 · CA
Genetic Targeting of T cells to B cell malignancies$134,436
K08 · FY2004 · CA
Genetic Targeting of T cells to B cell malignancies$134,196
K08 · FY2003 · CA